BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...
The company has also received FDA approval to initiate LEVEL-2, a global Phase 3 study for TNX-103 in PH-HFpEF, with the first patient expected to be enrolled later this year. This study aims to ...